Science for a better life

Bayer’s finerenone meets primary endpoint in Phase III FIDELIO-DKD renal outcomes study in patients with chronic kidney disease and type 2 diabetes

• Finerenone significantly reduced the combined primary endpoint of chronic kidney disease progression, kidney failure or kidney death versus placebo when added to standard of care • Finerenone significantly reduced the combined key secondary endpoint of cardiovascular death or non-fatal cardiovascular events • Chronic kidney disease impacts 4 in 10 patients with type 2 diabetes and is a deadly condition that is underrecognized • Finerenone is the first investigational non-steroidal, selective mineralocorticoid receptor antagonist to demonstrate renal and cardiovascular benefits in patients with chronic kidney disease and type 2 diabetes Read more

Bayer Inc. launches FastTRK, a complimentary clinical testing program for the diagnosis of NTRK gene fusions in TRK fusion cancer patients in Canada

Read more

Bayer announces agreements to resolve major legacy Monsanto litigation

Company will make a total payment of $10.1 billion to $10.9 billion (€9.1 billion to €9.8 billion) to resolve current and address potential future Roundup™ litigation/ • Company also resolves dicamba drift litigation for payment of up to $400 million and most PCB water litigation exposure for payment of approximately $820 million/ • Funding sourced from free cash flow and Animal Health divestment /• Bayer is well positioned to deliver science-based solutions to meet global health, nutrition needs Read more

Bayer completes the sale of its Animal Health business unit to Elanco

Read more